Available from stock

Anastrozole

SKU: A0802

Category: API's & Intermediates

Synonyms: Anastrol, ICI-D 1033, ZD 1033, ?,?,?',?'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile; 120511-73-1
CAS-Number: C₁₇H₁₉N₅
Molecular Formula: 293.37
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: White crystalline powder
Identity: 1H-NMR

Properties

Solvents: Soluble in DMF (10 mg/ml), DMSO (10 mg/ml), ethanol (20 mg/ml), methanol or chloroform.
Melting Point: 81 - 82 °C

Documentation

Safety Data Sheet (SDS): CDX A0802 SDS_Vs1.1.pdf

Shipping: AMBIENT
Short Term Storage: RT
Long Term Storage: +4°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at +4°C.

Hazard statements: H302,H360FD
Precautionary statements: P202 - P264 - P280 - P301 + P312 - P308 + P313 - P405
GHS Symbol: GHS07+GHS08
Signal word: Danger
Transportation: Not dangerous goods

Description: Anastrozole is a highly potent, non-steroidal aromatase inhibitor that selectively inhibits the aromatase enzyme (CYP19A1) responsible for converting androgens to estrogens. With an IC?? in the low nanomolar range (typically ~15 nM), it effectively suppresses estrogen synthesis, making it a key compound in hormone-related cancer research. It is selective for aromatase/CYP19A1 over the cytochrome P450 (CYP) isoforms CYP1A2, CYP2A6, CYP2C9, CYP2D6, and CYP3A. Anastrozole is widely used in studies of estrogen receptor-positive (ER?) breast cancer, endocrine resistance and hormone regulation. It is a standard reference compound in preclinical drug screening and mechanistic studies targeting estrogen biosynthesis. Compound can be used as analytical reference material in relation to doping analytics.
Smiles: CC(C)(C#N)C1=CC(CN2C=NC=N2)=CC(C(C)(C)C#N)=C1
InChi Key: YBBLVLTVTVSKRW-UHFFFAOYSA-N
References: (1) P.V. Plourde, et al., Breast Cancer Res. Treat. 30(1), 103-111 (1994) , (2) S.W. Grimm & M.C. Dyroff, Drug Metab. Dispos. 25, 598 (1997) , (3) P.E. Goss & L.M. Tye, Oncology 11, 1697 (1997) , (4) P.E. Lonning, et al., Breast Cancer Res. Treat. 49, S53 (1998) , (5) A.U. Buzdar, Br. J. Cancer 85, 6 (2001) , (6) P. Kubatka, et al., Anticancer Res. 28, 28193 (2008) , (7) J. Cairns, et al., Mol. Cancer Ther. 21, 206 (2022) , (8) O. Alomar, et al., Clin. Ther. 44, 1214 (2022) , (9) J. Sternberg, et al., Metabolites 15, 452 (2025)
InChi: InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3

Anastrozole is a highly potent, non-steroidal aromatase inhibitor that selectively inhibits the aromatase enzyme (CYP19A1) responsible for converting androgens to estrogens. With an IC?? in the low nanomolar range (typically ~15 nM), it effectively suppresses estrogen synthesis, making it a key compound in hormone-related cancer research. It is selective for aromatase/CYP19A1 over the cytochrome P450 (CYP) isoforms CYP1A2, CYP2A6, CYP2C9, CYP2D6, and CYP3A. Anastrozole is widely used in studies of estrogen receptor-positive (ER?) breast cancer, endocrine resistance and hormone regulation. It is a standard reference compound in preclinical drug screening and mechanistic studies targeting estrogen biosynthesis. Compound can be used as analytical reference material in relation to doping analytics.

SKU: A0802 Category: API's & Intermediates

Additional information

Additional information

Synonyms	Anastrol, ICI-D 1033, ZD 1033, ?,?,?',?'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Purity	≥98% (HPLC)
Appearance	White crystalline powder
CAS-Number	120511-73-1
Molecular Formula	C17H19N5
Molecular Weight	293.37
Identity	1H-NMR
Solvents	Soluble in DMF (10 mg/ml), DMSO (10 mg/ml), ethanol (20 mg/ml), methanol or chloroform.
Melting Point	81 – 82 °C
Smiles	CC(C)(C#N)C1=CC(CN2C=NC=N2)=CC(C(C)(C)C#N)=C1
InChi Key	YBBLVLTVTVSKRW-UHFFFAOYSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at +4°C.
Hazard statements	H302,H360FD
Precautionary statements	P202 – P264 – P280 – P301 + P312 – P308 + P313 – P405
GHS Symbol	GHS07+GHS08
Signal word	Danger
Transportation	Not dangerous goods
References	(1) P.V. Plourde, et al., Breast Cancer Res. Treat. 30(1), 103-111 (1994), (2) S.W. Grimm & M.C. Dyroff, Drug Metab. Dispos. 25, 598 (1997), (3) P.E. Goss & L.M. Tye, Oncology 11, 1697 (1997), (4) P.E. Lonning, et al., Breast Cancer Res. Treat. 49, S53 (1998), (5) A.U. Buzdar, Br. J. Cancer 85, 6 (2001), (6) P. Kubatka, et al., Anticancer Res. 28, 28193 (2008), (7) J. Cairns, et al., Mol. Cancer Ther. 21, 206 (2022), (8) O. Alomar, et al., Clin. Ther. 44, 1214 (2022), (9) J. Sternberg, et al., Metabolites 15, 452 (2025)
InChi	InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
Quantity	500 mg, 1 g, Bulk